{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:55Z","timestamp":1794047515704,"version":"4.8.0"},"reference-count":27,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Triplet regimens with a hypomethylating agent, venetoclax and a FLT3 inhibitor yield high rates of response in newly diagnosed FLT3-mutated acute myeloid leukemia (AML). However, the long-term outcomes and patterns of relapse with these triplet regimens are not well-established. In this retrospective analysis, 73 patients with newly diagnosed FLT3-mutated AML received a frontline FLT3 inhibitor-containing triplet regimen. The composite complete remission and complete remission with incomplete hematologic recovery rate was 93%. According to next-generation sequencing (sensitivity: 0.005%), FLT3-ITD minimal residual disease negativity was achieved in 60% of patients after cycle 2 and 90% after cycle 4. The estimated 3-year relapse-free survival for FLT3-ITD-mutated and FLT3 TKD-mutated AML was 38% and 76%, respectively, and the 3-year overall survival (OS) was 45% and 76%, respectively. Neither age, NPM1 co-mutation, European LeukemiaNet 2022 risk category, nor allogeneic stem cell transplantation in first remission significantly impacted OS. Baseline RAS pathway mutations were associated with poor long-term survival (3-year OS 22% vs. 63% in those without a RAS pathway mutation). FLT3 wild-type relapses accounted for 65% of relapses, and new RAS pathway mutations were observed in 24% of relapses. Outcomes were poor after relapse (median OS of 6.1 months), particularly for those with persistently detectable FLT3 mutations. Triplet combinations of a hypomethylating agent, venetoclax and a FLT3 inhibitor result in durable remission and encouraging long-term OS in older adults with newly diagnosed FLT3-mutated AML. However, better strategies to prevent FLT3 wild-type relapses and to overcome RAS pathway-mediated resistance are still needed.<\/jats:p>","DOI":"10.3324\/haematol.2025.288553","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T07:40:54Z","timestamp":1759390854000},"page":"1246-1253","source":"Crossref","is-referenced-by-count":13,"title":["Long-term outcomes in &lt;i&gt;FLT3&lt;\/i&gt;-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor"],"prefix":"10.3324","volume":"111","author":[{"given":"Nicholas J.","family":"Short","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musa","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Karrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunhwa","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney D.","family":"Dinardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan M.","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Maroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghayas C.","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betul","family":"Oran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Shpall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uday","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Routbort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naval","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"87592","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Jonas BA, Pullarkat V. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020; 383(7):617-629.","DOI":"10.1056\/NEJMoa2012971"},{"key":"87593","doi-asserted-by":"crossref","unstructured":"Konopleva M, Thirman MJ, Pratz KW. Impact of FLT3 mutation on outcomes after venetoclax and azacitidine for patients with treatment-na\u00efve acute myeloid leukemia. Clin Cancer Res. 2022; 28(13):2744-2752.","DOI":"10.1158\/1078-0432.CCR-21-3405"},{"key":"87594","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Tiong IS, Quaglieri A. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020; 135(11):791-803.","DOI":"10.1182\/blood.2019003988"},{"key":"87595","doi-asserted-by":"crossref","unstructured":"Short NJ, Nguyen D, Ravandi F. Treatment of older adults with FLT3-mutated AML: emerging paradigms and the role of frontline FLT3 inhibitors. Blood Cancer J. 2023; 13(1):142.","DOI":"10.1038\/s41408-023-00911-w"},{"key":"87596","doi-asserted-by":"crossref","unstructured":"Ohanian M, Garcia-Manero G, Levis M. Sorafenib combined with 5-azacytidine in older patients with untreated FLT3-ITD mutated acute myeloid leukemia. Am J Hematol. 2018; 93(9):1136-1141.","DOI":"10.1002\/ajh.25198"},{"key":"87597","doi-asserted-by":"crossref","unstructured":"Swaminathan M, Kantarjian HM, Levis M. A phase I\/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica. 2021; 106(8):2121-2130.","DOI":"10.3324\/haematol.2020.263392"},{"key":"87598","doi-asserted-by":"crossref","unstructured":"Wang ES, Montesinos P, Minden MD. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. Blood. 2022; 140(17):1845-1857.","DOI":"10.1182\/blood.2021014586"},{"key":"87599","doi-asserted-by":"crossref","unstructured":"Short NJ, Daver N, DiNardo CD. Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML. J Clin Oncol. 2024; 42(13):1499-1508.","DOI":"10.1200\/JCO.23.01911"},{"key":"87600","doi-asserted-by":"crossref","unstructured":"Yilmaz M, Muftuoglu M, Short NJ. Phase I\/II study of decitabine, venetoclax, and quizartinib triplet combination in FLT3-ITD mutated AML. EHA Library. 2025; 4159219:S142.","DOI":"10.1182\/blood-2023-186699"},{"key":"87601","doi-asserted-by":"crossref","unstructured":"Maiti A, DiNardo CD, Daver NG. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J. 2021; 11(2):25.","DOI":"10.1038\/s41408-021-00410-w"},{"key":"87602","unstructured":"Bataller A, Short NJ, Daver N. Phase 1\/2 study of oral decitabine\/cedazuridine with venetoclax and gilteritinib in patients with newly diagnosed and relapsed\/refractory acute myeloid leukemia. EHA Library. 2024; 422243:S139."},{"key":"87603","unstructured":"Daver N, Perl AE, Wang E. VICEROY: a phase I\/II study of gilteritinib, venetoclax and azacitidine combination in patients with newly diagnosed FLT3-mutated acute myeloid leukemia ineligible for intensive induction chemotherapy. EHA Library. 2024; 421201:PB2454."},{"key":"87604","doi-asserted-by":"crossref","unstructured":"Short NJ, Kantarjian HM, Loghavi S. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol. 2019; 6(1):e29-e37.","DOI":"10.1016\/S2352-3026(18)30182-0"},{"key":"87605","doi-asserted-by":"crossref","unstructured":"Luthra R, Patel KP, Reddy NG. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica. 2014; 99(3):465-473.","DOI":"10.3324\/haematol.2013.093765"},{"key":"87606","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140(12):1345-1377.","DOI":"10.1182\/blood.2022016867"},{"key":"87607","doi-asserted-by":"crossref","unstructured":"Jen WY, Sasaki K, Ravandi F. Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy. Blood Adv. 2025; 9(4):783-792.","DOI":"10.1182\/bloodadvances.2024013826"},{"key":"87608","doi-asserted-by":"crossref","unstructured":"Wang SA, Jorgensen JL, Hu S. Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal\/ measurable residual disease detection. Cytometry B Clin Cytom. 2023; 104(5):356-366.","DOI":"10.1002\/cyto.b.22140"},{"key":"87609","doi-asserted-by":"crossref","unstructured":"Erba HP, Montesinos P, Kim H-J. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023; 401(10388):1571-1583.","DOI":"10.1016\/S0140-6736(23)00464-6"},{"key":"87610","doi-asserted-by":"crossref","unstructured":"Ivey A, Hills RK, Simpson MA. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016; 374(5):422-433.","DOI":"10.1056\/NEJMoa1507471"},{"key":"87611","doi-asserted-by":"crossref","unstructured":"Othman J, Potter N, Ivey A. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood. 2024; 143(19):1931-1936.","DOI":"10.1182\/blood.2023023096"},{"key":"87612","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, DiNardo CD, Appelbaum FR. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024; 144(21):2169-2173.","DOI":"10.1182\/blood.2024025409"},{"key":"87613","doi-asserted-by":"crossref","unstructured":"McMahon CM, Ferng T, Canaani J. Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discov. 2019; 9(8):1050-1063.","DOI":"10.1158\/2159-8290.CD-18-1453"},{"key":"87614","doi-asserted-by":"crossref","unstructured":"Kennedy V, Peretz C, Lee P. Multi-omic single-cell sequencing reveals genetic and immunophenotypic clonal selection in patients with FLT3-mutated AML treated with gilteritinib\/venetoclax. Blood. 2022; 140(Supplement 1):2244-2246.","DOI":"10.1182\/blood-2022-160304"},{"key":"87615","doi-asserted-by":"crossref","unstructured":"Borthakur G, Popplewell L, Boyiadzis M. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer. 2016; 122(12):1871-1879.","DOI":"10.1002\/cncr.29986"},{"key":"87616","doi-asserted-by":"crossref","unstructured":"Desikan SP, Ravandi F, Pemmaraju N. A phase II study of azacitidine, venetoclax, and trametinib in relapsed or refractory acute myeloid leukemia harboring RAS pathway-activating mutations. Acta Haematol. 2022; 145(5):529-536.","DOI":"10.1159\/000525566"},{"key":"87617","doi-asserted-by":"crossref","unstructured":"Bataller A, Kantarjian HM, Bazinet A. Phase II study of cladribine with low dose cytarabine and venetoclax alternating with azacytidine and venetoclax for newly diagnosed acute myeloid leukemia. Blood. 2024; 144(Supplement 1):56.","DOI":"10.1182\/blood-2024-202620"},{"key":"87618","doi-asserted-by":"crossref","unstructured":"Schmalbrock LK, Dolnik A, Cocciardi S. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood. 2021; 137(22):3093-3104.","DOI":"10.1182\/blood.2020007626"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/12909\/78911","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12909\/79861","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12909\/78911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:09:55Z","timestamp":1794046195000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/12909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2025.288553","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,2]]}}}